Certara (NASDAQ:CERT) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Certara (NASDAQ:CERT) from a buy rating to a hold rating in a research note published on Sunday.

A number of other research analysts have also recently weighed in on the company. Leerink Partners upgraded Certara from a “market perform” rating to an “outperform” rating and set a $13.00 price target for the company in a research report on Tuesday, January 6th. KeyCorp dropped their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Stephens lowered their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. Finally, BMO Capital Markets began coverage on shares of Certara in a research note on Thursday, November 13th. They set a “market perform” rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.82.

Certara Stock Performance

Shares of CERT stock opened at $6.51 on Friday. The stock’s 50-day moving average price is $8.71 and its 200 day moving average price is $10.09. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1.04 billion, a PE ratio of 93.00 and a beta of 1.47. Certara has a 52-week low of $6.45 and a 52-week high of $15.38.

Institutional Trading of Certara

A number of institutional investors and hedge funds have recently bought and sold shares of the business. First Horizon Corp acquired a new position in Certara in the 3rd quarter worth $30,000. Versant Capital Management Inc increased its position in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after acquiring an additional 1,153 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Certara during the 2nd quarter valued at approximately $59,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.